People: Galapagos NV (GLPG.AS)
21 Aug 2019
Dr. Rajesh (Raj) B. Parekh has been Non-Executive Chairman of the Board of Galapagos NV since July 2004. He is also Chairman of the Company's Nomination and Remuneration Committee. He is a General Partner at Advent Life Sciences LLP, which he joined in 2006. During an academic career at Oxford University, he co-founded Oxford GlycoSciences PLC, where he served as Chief Scientific Officer and Chief Executive Officer from 1988 until its sale to Celltech Group PLC (now UCB SA) in 2003. He has founded or served on the boards of several life sciences companies in the United States and Europe including Celldex Therapeutics, Inc.; Avila Therapeutics, Inc.; EUSA Pharma (Europe) Limited; Thiakis Limited; and Amsterdam Molecular Therapeutics (AMT) Holding N.V. (now uniQure). Dr. Parekh currently serves as a member of the board of directors of Advent Venture Partners; Advent Life Sciences LLP; Aleta Inc.; Arrakis, Inc.; Aura Inc.; Artax Inc.; Capella BioSciences Ltd.; Cellnovo Limited; EnCipher Limited; Itara Limited; Levicept Limited; Macrolide Pharmaceuticals, Inc.; PE Limited; and Project Paradise Limited. He is also a member of the supervisory board of the Novartis Venture Fund. During the past five years, he served as a member of the board of directors of Biocartis NV, 4-Antibody AG, NeRRe Therapeutics Limited, F2G Limited, LuxFold S.A., CoCo Therapeutics Limited. He received his MA in Biochemistry and DPhil in Molecular Medicine from the University of Oxford, where he was a Senior Research Fellow and Professor.
|Total Annual Compensation, EUR||91,000|
|Restricted Stock Award, EUR||--|
|Long-Term Incentive Plans, EUR||--|
|All Other, EUR||--|
|Fiscal Year Total, EUR||91,000|